Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.63 |
| ▸ | HTR3B | O95264 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.63 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | PRKDC | P78527 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349056 | 0.98 | AKR1C3 (0.66) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL18415522 | 0.94 | AKR1C3 (0.62) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| Nitrogen SCHEMBL7794313 | 0.94 | AKR1C3 (0.62) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL10680649 | 0.90 | AKR1C3 (0.58) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL5793905 | 0.89 | RAB9A (0.69) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL10770587 | 0.89 | MAPT (0.66) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL19831125 | 0.89 | GSK3B (0.65) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL6740893 | 0.88 | MAPT (0.86) | AKR1C3MAPTRAB9AL3MBTL1KMT2A | |
| SCHEMBL29656856 | 0.87 | HTR3E (0.73) | AKR1C3MAPTRAB9AL3MBTL1HTR3E | |
| SCHEMBL28599511 | 0.87 | HTR3E (0.73) | AKR1C3MAPTRAB9AL3MBTL1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | UNIV RUTGERS (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4452488-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | Rutgers, The State University Of New Jersey (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2024-10-03 | — | — | US | disclosed |
| EP-3845546-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-3842421-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2024-06-12 | — | — | EP | disclosed |
| EP-4277745-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | UVIC Industry Partnerships Inc. (CA) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023122078-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11649258-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649258-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649258-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2023-05-16 | — | — | US | disclosed |
| EP-1149094-B1 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| EP-1354887-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Insitute of Technology (US) | 2003-10-22 | — | — | EP | disclosed |
| CN-1416954-A | Phosphinidene amide and transition metal complex catalyst and its synthesis process and application in C-C and C-N bond forming reaction | SHANGHAI INST ORGANIC CHEM (CN) | 2003-05-14 | — | — | CN | disclosed |
| US-6562989-B2 | Bicyclopentyl iron ligand and transition metal catalyst | YALE UNIVERSITY | 2003-05-13 | — | — | US | disclosed |
| US-20030008768-A1 | Catalyst for aromatic C-O, C-N, and C-C bond formation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
| US-4626591-A | Trans-dl-1-alkyl-6-alkoxy-1,2,3,4,4a,5,8,8a octa-hydroquinolines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4540787-A | Method of preparing trans-D1-1-alkyl-6-oxodecahydroquinolines | ELI LILLY AND COMPANY (US) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | PDCD6IP, PDPK1, PDCD10 | AKR1C3 4001/4885MAPT 4667/4885RAB9A 3105/4885 |
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | NDC1, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AKR1C3 3932/4885MAPT 4268/4885RAB9A 1451/4885 |
| US-11649258-B2 | Complexes | AP2M1, AP1M1, INF2 | AKR1C3 1799/4885MAPT 4216/4885RAB9A 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.